Global Gene Panel Market : Industry Size, Share, Analysis, Trend & Future Planning 2023
Bharat Book Bureau Provides the Trending Market Research Report on “Global Gene Panel Market, Forecast to 2023” underLife Sciences category. The report offers a collection of superior market research, market analysis, competitive intelligence and industry reports.
Global gene panels market projected to grow at aCAGR of 19.2%
The global gene panels market is expected to reachUSD 2.95 billion by 2023 from USD 1.22 billion in 2018, at a CAGR of 19.2%. This market is experiencing significant growth due increasing prevalence of chronic diseases, growing company initiatives (in terms of strategic partnerships, collaborations, and product launches), and growing adoption of gene panels owing to the benefits they offer. However, issues related to the security of genetic data and accuracy & standardization concerns in diagnostic testing are restricting the growth of this market
Request a free sample copy ofGene Panel MarketReport @ https://www.bharatbook.com/MarketReports/Sample/Reports/1103628
The testing services segment is projected to grow at the highest CAGR during the forecast period
Based on product & service, the market is segmented into test kits and testing services. The test services segment is projected to register the highest CAGR during the forecast period. Factors such as the increasing focus of market players on providing efficient gene panel services to researchers and the growing number of government funding programs for genomic research are likely to drive the market for gene panel testing services.
By application, the cancer risk assessment segment held the largest share of the market during the forecast period
Based on applications, the market is segmented into cancer risk assessment, diagnosis of congenital diseases, pharmacogenetics, and other applications. The cancer risk assessment segment held the largest share of the gene panels market in 2018. It is also projected to register the highest growth during the forecast period due to the increasing incidence of cancer and the growing demand for gene panels in research and diagnostics to understand the genetic variability of cancer.
North America to witness the highest growth during the forecast period
In 2018, North America is expected to account for the largest share of the market followed by Europe. North America is also projected to register the highest CAGR during the forecast period. This can be attributed to factors such as the government support for genomics research, presence of leading NGS providers, and growing research on cancer and inherited rare diseases in the region.
The primary interviews conducted for this report can be categorized as follows:
- By Company Type: Tier 1 – 30%; Tier 2 - 42%; Tier 3 - 28%
- By Designation: C-level- 25%; D-level- 45%; Others- 30%
- By Region: North America-48%; Europe-29%; Asia Pacific-19%; Rest of the World-4%
List of companies profiled in the report
- Illumina, Inc. (US)
- Thermo Fisher Scientific (US)
- Agilent Technologies (US)
- QIAGEN (Germany)
- BGI (China)
- Eurofins Scientific (US)
- F. Hoffmann-La Roche AG (Switzerland)
- Integrated DNA Technologies (US)
- GATC Biotech AG (Germany)
- GENEWIZ, Inc. (US)
- Novogene Corporation (China)
- Personalis (US)
- ArcherDx (US)
Click the link below to read the Full report :
https://www.bharatbook.com/MarketReports/Gene-Panel-Market-by-Product-Service-Technique-Amplicon-Hybridization-Design-Predesign-Custom-Application-Cancer-Congen/1103628
About Bharat Book Bureau:
Bharat Book Bureau is the leading market research information provider for market research reports, company profiles, industry study, country reports, business reports, newsletters and online databases. Bharat Book Bureau provides over a million reports from more than 400 publishers around the globe. We cover sectors starting from Aeronautics to Zoology.
Contact us at:
Bharat Book Bureau
Tel: +91 22 27810772 / 27810773
Email:poonam@bharatbook.com
Website:www.bharatbook.com
Follow us on: Twitter, Facebook, LinkedIn, Google Plus
Hepion Pharmaceuticals' (Nasdaq: HEPA) CRV431 Prevents Cirrhosis in Experimental Model of Severe Liver Disease
